1 Ability of a polygenic risk score to refine colorectal cancer

2

risk in Lynch syndrome

3 Authors

Nuria Dueñas*^{1,2,3}, Hannah Klinkhammer*^{4,5}, Nuria Bonifaci*^{2,3}, Isabel Spier^{6,7,8}, 4 Hassanin⁵, Anna Díez-Villanueva^{9,10,11}, Mayr⁴, Emadeldin Victor 5 Andreas Moreno^{9,10,11,12}, Marta Pineda^{1,2,3}, Carlo Maj⁵, Gabriel Capellá^{1,2,3,8}, Stefan Aretz^{**+6,7,8}, 6 Joan Brunet***1,2,3,8,13 7 8 1. Hereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain. nduenas@iconcologia.net, 9 mpineda@iconcologia.net, gcapella@idibell.cat, jbrunet@iconcologia.net 10 2. Program in Molecular Mechanisms and Experimental Therapy in Oncology (ONCOBELL), Bellvitge Biomedical Research Institute 11 (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. nduenas@iconcologia.net, nbonifaci@idibell.cat, mpineda@iconcologia.net, 12 gcapella@idibell.cat, jbrunet@iconcologia.net 13 3. Biomedical Research Centre Network for Oncology (CIBERONC), Instituto Salud Carlos III, Madrid, Spain. 14 nduenas@iconcologia.net, mpineda@iconcologia.net, gcapella@idibell.cat, jbrunet@iconcologia.net 15 4. Institute for Medical Biometry, Informatics and Epidemiology, Medical Faculty, University of Bonn, Germany. 16 klinkhammer@imbie.uni-bonn.de, amayr@uni-bonn.de 17 5. Institute for Genomic Statistics and Bioinformatics, Medical Faculty, University of Bonn, Germany. klinkhammer@imbie.uni-18 bonn.de, emadsf1992@gmail.com, cmaj@uni-bonn.de 19 6. Institute of Human Genetics, Medical Faculty, University of Bonn, Germany. isabel.spier@uni-bonn.de, stefan.aretz@uni-20 bonn.de. 21 7. National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Germany, isabel.spier@uni-bonn.de, 22 stefan.aretz@uni-bonn.de 23 8. European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS). isabel.spier@uni-bonn.de, 24 gcapella@idibell.cat, mpineda@iconcologia.net, stefan.aretz@uni-bonn.de, jbrunet@iconcologia.net 25 9. Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain. 26 adiez@iconcologia.net. v.moreno@iconcologia.net 27 10. Colorectal Cancer Group (ONCOBELL), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, 28 Spain. adiez@iconcologia.net, v.moreno@iconcologia.net 29 11. Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), Instituto Salud Carlos III, Madrid, Spain. 30 adiez@iconcologia.net, v.moreno@iconcologia.net 31 12. Department of Clinical Sciences, Faculty of Medicine and Health Sciences and Universitat de Barcelona Institute of Complex 32 Systems (UBICS), University of Barcelona, Barcelona, Spain. v.moreno@iconcologia.net 33 13. Hereditary Cancer Program, Catalan Institute of Oncology-IDBIGI, Girona, Spain. jbrunet@iconcologia.net 34 * These authors contributed equally to this work and share first authorship ** These authors contributed equally to this work and share last authorship 35 ⁺ These authors act as corresponding authors 36

37

38 **ABSTRACT:**

39 Background: Polygenic risk scores (PRS) have been used to stratify colorectal cancer 40 (CRC) risk in the general population, whereas its role in Lynch syndrome (LS), the most 41 common type of hereditary CRC, is still conflicting. We aimed to assess the ability of 42 PRS to refine CRC risk prediction in European-descendant LS individuals.

Methods: 1,465 LS individuals (557 *MLH1*, 517 *MSH2/EPCAM*, 299 *MSH6*, and 92 *PMS2*) and 5,656 CRC-free population-based controls from two independent cohorts were included. A 91-Single Nucleotide Polymorphism PRS was applied. A Cox proportional hazard regression model with "family" as a random effect and a logistic regression analysis, followed by a meta-analysis combining both cohorts were conducted.

49 **Results:** Overall, we did not observe a statistically significant association between PRS 50 and CRC risk in the entire cohort. Nevertheless, PRS was significantly associated with a 51 slightly increased risk of CRC or advanced adenoma (AA), in those with CRC 52 diagnosed < 50 years, and in individuals with multiple CRCs or AAs diagnosed < 60 53 years.

54 **Conclusion:** The PRS may slightly influence CRC risk in LS individuals, in particular in 55 more extreme phenotypes such as early-onset disease. However, the study design and 56 recruitment strategy strongly influence the results of PRS studies. A separate analysis 57 by genes and its combination with other genetic and non-genetic risk factors will help 58 refine its role as a risk modifier in LS.

59

60	
61	
62	
63	KEY MESSAGES:
64	WHAT IS ALREADY KNOWN ON THIS TOPIC?
65	- Great variability in the incidence of CRC has been described in LS individuals,
66	even within the same family.
67	- Polygenic risk scores (PRS) can help stratify colorectal cancer risk and, thus,
68	adjust surveillance or treatment procedures.
69	WHAT THIS STUDY ADDS
70	- PRS performed on family-based registries slightly influences CRC risk in
71	subgroups of LS individuals, even though with weak effects.
72	- Our study showed a weak association of PRS with multiple and young CRC
73	cases, pointing to a possible risk-modifying role in extreme phenotypes.
74	HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
75	- Gene-based PRS analysis and its combination with other genetic and non-
76	genetic factors may contribute to refining cancer risk in LS patients.
77	

78 INTRODUCTION

Colorectal cancer (CRC) is the third most incident cancer overall and the second leading cause of cancer-related death worldwide. Incidence rates are four times higher in the Global North, associated with lifestyle and dietary risk factors¹.

82 About 5% of CRC is considered hereditary due to highly penetrant pathogenic germline variants in cancer-predisposing genes^{2,3}. The main cause of hereditary CRC is Lynch 83 84 Syndrome (LS), with an estimated carrier frequency in the general population of around 85 1:279⁴. It is characterised as an autosomal dominant inherited defect in any of the 86 mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) or EPCAM gene deletions, resulting in silencing of the MSH2 gene in epithelial tissues⁵. Median CRC 87 88 cumulative incidences at 75 years show an important variability according to mutated 89 gene and gender: 48/57%, 47/51%, and 18/20% for male and female carriers of 90 mutations in MLH1, MSH2, and MSH6, respectively, and 10% for both genders in carriers of mutations in PMS2⁶. Differences in CRC risk have also been identified based 91 92 on the ethnic or geographical origin of carriers, with lower risks reported for European vs. American and Australasian individuals⁷. Moreover, LS carriers have an increased 93 94 risk of developing multiple CRCs, CRC at a younger age, and other LS-associated 95 cancers such as endometrial (EC) or ovarian cancer⁶.

96 In LS, as in other hereditary cancer predisposition syndromes characterised by 97 incomplete penetrance, one of the main challenges is to identify which risk-modifying 98 factors may modulate the expression of the cancer syndrome^{7,8}. In recent years, 99 multiple, common, low-penetrance CRC risk variants have been identified through 100 genome-wide association studies (GWAS)^{9–11}. Each risk allele individually confers a

101 small risk, but their combined effect as a polygenic risk score (PRS) exhibits significant 102 risks of developing CRC in the general population. Being in the highest PRS percentiles was shown to increase the risk of CRC two- to seven-fold^{10,12–16}. Moreover, PRS might 103 104 be particularly relevant in patients with a more extreme, i.e., severe, phenotype: a study 105 performed in individuals diagnosed with CRC before 50 years of age (early-onset 106 disease) demonstrated the existence of an interaction between PRS and CRC risk, with an odds ratio (OR) of 3.73 (3.28-4.24) in the highest PRS guartile¹⁷. Another study on 107 108 familial CRC (individuals who fulfil Amsterdam or Bethesda criteria without a pathogenic 109 germline MMR variant) identified an increased CRC risk in individuals in the highest 5% 110 of the PRS distribution, with an OR of $4.89 (2.37-10.07)^{18}$.

To date, the modulating effect of PRS on CRC risk in LS individuals is still controversial. Two studies on a population-based repository from the UK Biobank (UKBB) including 76 and 388 LS carriers, respectively, reported that PRS may strongly influence CRC risk^{16,19}; however, another analysis of the clinic-based registry of the Colon Cancer Family Registry (CCFR), including 826 European-descendant LS individuals, found no evidence of association, irrespective of sex or mutated gene²⁰.

Our objective was to evaluate whether differences in CRC penetrance in European descendant LS individuals can, in part, be explained by the accumulation of low-risk
 CRC alleles using a validated set of 91 SNPs for PRS analysis.

120

121 METHODS

- 122 Study participants
- 123 LS individuals:

124 A total of 1,465 European-descendant individuals with genetically confirmed LS (557 125 MLH1, 517 MSH2/EPCAM, 299 MSH6, and 92 PMS2) from two independent cohorts 126 were included: 918 LS individuals (353 families) identified at the Catalan Institute of 127 Oncology (ICO; Spain) and 547 LS individuals (392 families) from the University 128 Hospital of Bonn (UKB; Germany). Patients were recruited based on the fulfilment of 129 Bethesda or Amsterdam criteria or via an EC and CRC-based LS screening programme 130 (since 2016 at the ICO)²¹. Patients included were affected index patients and affected or 131 unaffected carriers among the relatives identified through cascade testing. In the ICO 132 LS cohort, there was a lower percentage of pathogenic MSH2 variant carriers (mainly 133 due to the existence of MLH1 founder mutations in the ICO series) and a higher 134 percentage of pathogenic MSH6 and PMS2 variant carriers (mainly identified through 135 an EC/CRC-based LS screening) when compared with the UKB LS cohort. In addition, 136 the ICO cohort included a higher proportion of non-index individuals. There were no 137 significant differences in the distribution of affected genes between early-onset cases 138 and the entire cohort (Table 1).

All patients gave informed consent and the internal Ethics Committee approved thisstudy.

141 Non-LS individuals:

A total of 5,656 unselected CRC-free individuals from the same population were included in the analysis (CRC-free population controls): 1,642 individuals from Spain and 4,014 from Germany. The controls from Spain included individuals from the CRCGEN study and individuals participating in a population-based CRC screening program, most of whom had a positive faecal immunochemical test (FIT) result and a

- 147 colonoscopy without cancer or advanced adenoma, as described elsewhere²². The
- 148 German controls were drawn from the population-based Heinz Nixdorf RECALL (HNR)
- 149 study (Risk Factors, Evaluation of Coronary Calcification, and Lifestyle) as described
- 150 recently²³ (*Table 1*).

	Lyr	nch syndro	me	Population controls			
	All series	ICO	UKB	All series	Spain	Germany	
Total n of individuals	1465	918	547	5656	1642	4014	
	(100%)	(62.7%)	(37.3%)	(100%)	(29.0%)	(70.1%)	
Age							
Mean age at censor	45.6 (12-	47.9 (16-	41.6 (12-	71.0 (24-	62.4 (24-	74.5 (49-	
(range)	93)	93)	86)	94)	92)	94)	
Gender							
Male	707	409	298	2813	835	1978	
Maic	(48.3%)	(44.6%)	(54.5%)	(49.7%)	(50.9%)	(49.3%)	
Female	758	509	249	2843	807	2036	
	(51.7%)	(55.4%)	(45.5%)	(50.3%)	(49.2%)	(50.7%)	
Mutated gene							
MLH1	557	346	211	_	_	_	
	(38.0%)	(37.7%)	(38.6%)				
MSH2/EPCAM	517	247	270	_	_	_	
	(35.3%)	(26.9%)	(49.4%)				
MSH6	299	250	49 (9.0%)	_	_	_	
	(20.4%)	(27.2%)	10 (0.070)				
PMS2	92	75	17	_	_	_	
1 1002	(6.3%)	(8.2%)	(3.1%)				
Index case							
Yes	590	193	397	-	-	-	
	(40.3%)	(21.0%)	(72.6%)				
No	875	725	150	-	_	_	
	(59.7%)	(79.0%)	(27.4%)				

151 **TABLE 1:** Main characteristics of the population studied.

152 ICO: Catalan Institute of Oncology, Spain; UKB: University Hospital of Bonn, Germany

153

154 Data collection

155 Clinical data included demographic, personal and oncologic history, and follow-up

156 carried out from birth to 06/2021. In LS individuals, histories of colorectal polyps or other

LS-related cancers were also collected. Data supporting the results were stored in localdatabases at both centres.

159 SNP selection

The selected SNPs (n=95) and associated risks were obtained from the meta-analysis of CRC risk alleles performed by Huyghe *et al.*,¹⁰ (*Tab. S1*) and were commonly used to study sporadic CRC risk at the initiation of the study^{16,19}. Individual CRC risk-associated SNPs reached independent genome-wide significance ($p < 5x10^{-8}$) in a large-scale GWAS.

165 **Genotyping**

ICO blood DNA samples were genotyped with the Illumina Global Screening Array-24 166 167 (GSA) v2.0 v3.0 (https://emea.illumina.com/science/consortia/humanand 168 consortia/global-screening-consortium.html) and UKB samples with GSA v3.0. Of note, 169 48% of the ICO population of CRC-free individuals were previously included in the meta-analysis by Huyghe et al.,¹⁰ however, they corresponded to ~1% of the total 170 171 number of cases and controls in the analysis. Details regarding quality control procedures and correlation between arrays have been described previously^{18,22}. 172

173 Non-European-descendant individuals were excluded from the analysis. To assess 174 ethnicity, Spanish samples were compared with 1,397 HapMap samples, while German 175 samples were compared with 1k genome samples. Classification into different ethnicity 176 groups was performed by selecting ancestry-informative marker SNPs (AIM SNPs) and 177 using a principal components analysis (PCA) approach.

178 Imputation

179 Thirteen and eighteen of the 95 variants of interest were included in the Illumina GSA-180 24 v2.0 and v3.0, respectively. Variants not directly genotyped by the corresponding 181 arrays were imputed in the ICO with the Michigan Imputation Server (HRC version r1.1.2016 panel)²⁴ and in the UKB with a comparable pipeline based on the 182 183 bioinformatic tools beftools, minimae, and veftools, using GRCh37 as the reference genome (1000 Genomes, phase 3, v5)²⁵. Missing variants and variants with an 184 185 imputation quality $(r^2) < 0.3$ (considering all genotyped samples) were not included in the final PRS analysis, which resulted in the exclusion of rs6058093, rs35470271, 186 187 rs145364999, and rs755229494 (Tab. S1).

188 **PRS calculation**

For each participant, PRS was computed using the PLINK score function²⁶, based on the 91 quality-controlled CRC risk alleles (coded as 0, 1, or 2) and effect sizes as reported by Huyghe *et al.*, (PRS) and averaged over the number of observed variants per individual¹⁰ (wPRS). To ease interpretation, wPRS values were rescaled (rwPRS) to indicate risk per allele (using the ratio of non-averaged PRS and wPRS values in controls as a scaling factor) as previously reported¹⁸.

195 Study events

Two events were considered: i) CRC and ii) advanced adenoma (AA) (adenoma with significant villous features (>25%), size \geq 1.0 cm, high-grade dysplasia, or early invasive cancer).

Two subgroups were defined for the primary analysis: affected individuals (CRC and CRC or AA LS individuals) and unaffected individuals (CRC-free or CRC-free and AAfree LS individuals). For the subanalysis of multiple CRCs, three subgroups were

defined: multiple events (multiple CRC and multiple CRC or AA LS individuals), single event (single CRC and single CRC or AA LS individuals) and no-event (CRC-free and CRC-free and AA-free LS individuals). CRC-free population controls were only compared to CRC or multiple CRC LS individuals when considering CRC as a study event as no reliable information was available regarding AA in this population. *(Tab. S2,*

207 Tab. S3, and Fig. S1).

208 Statistical methods

209 Statistical analyses and graphical representations were conducted with R version 4.0.5. 210 For the primary analysis, the association of rwPRS with CRC and CRC or AA risk was 211 tested by considering time to CRC (years since birth to event of study) using a Cox 212 proportional hazard regression model with family as a random effect (frailty model). 213 Observations in the control cohort were right censored at the age of last contact and 214 CRC diagnosis (yes/no) was used as an event variable. The date of the first 215 polypectomy for adenoma was used as a time-dependent variable. Additionally, sex, 216 birth cohort (<1940, 1940-49, 1950-59, 1960-69, 1970-79, >1980), and other LS-related 217 cancers were included as covariates.

For the subanalysis of multiple CRCs, the association of rwPRS with multiple CRCs or AAs was tested using a mixed effects logistic regression, including age, sex, birth cohort, polypectomy before the second CRC, the occurrence of other cancers, and family (random effect) as covariates.

Results from both cohorts (ICO and UKB) were combined and analysed via a fixedeffect meta-analysis and the inverse-variance method. The combined rwPRS effect was estimated as the weighted average of the estimates of the individual studies and

225 weights were derived as the inverse of the variance of the individual effect estimate. 226 The population was stratified according to rwPRS tertiles using the medium category as 227 a reference. Additionally, to test for heterogeneity, Cochran's Q was computed on the 228 derived estimates and a χ^2 -test with one degree of freedom was performed. Results 229 with p-values <0.05 in the test for heterogeneity were not considered. The metaanalysis was conducted via R package meta²⁷. To correct for multiple testing, analyses 230 231 were grouped by study event and control group, and p-values inside these groups were corrected via false discovery rate (FDR) correction²⁸. Only results with p-values <0.05 232 233 after FDR correction (p-FDR) were considered statistically significant.

234

235 **RESULTS**

236 No differences in PRS distribution were observed when comparing CRC-free LS 237 individuals and CRC-free population controls in any of the cohorts studied *(Fig. S2)*.

238 **Primary analysis**

239 CRC as the study event

A statistically significant association of rwPRS with CRC risk was found in LS carriers under 50 years of age compared with CRC-free LS individuals (HR=1.022 [1.007-1.038], *p*-FDR=0.01). We found a tendency for an association of rwPRS with CRC risk in the entire cohort and *MSH6* variant carriers. We found no statistically significant association of rwPRS with CRC risk when comparing CRC LS to CRC-free population individuals (*Table 2 and Tab. S4*).

Additionally, rwPRS tended to be associated with higher CRC risk in *MSH2/EPCAM* (tertile low: HR=0.716 [0.505-1.016], *p*-FDR= 0.53 vs. tertile high: HR=1.058 [0.769-

- 248 1.455] p-FDR=0.96) and MSH6 variant carriers (tertile low: HR=0.617 [0.299-1.271], p-
- 249 FDR=0.53 vs. tertile high: HR=1.594 [0.929-2.735], *p*-FDR=0.53), however, results were
- 250 not statistically significant (*Figure 1*).
- 251 CRC or AA as study events
- 252 A statistically significant association of rwPRS with CRC or AA risk was observed in the
- entire cohort (HR=1.019 [1.005-1.032], *p*-FDR=0.03) and in LS carriers under 50 years
- 254 of age (HR=1.022 [1.006-1.038], *p*-FDR=0.006). We observed a tendency for an
- association of rwPRS with CRC or AA risk in MSH2/EPCAM and MSH6 carriers (Table
- 256 **2 and Tab. S5)**.
- Even though no statistically significant associations were observed *(Figure 2)*, rwPRS tended to be associated with a higher risk of CRC and AA in *MSH6* variant carriers (tertile low: HR=0.669 [0.322-1.393], *p*-FDR=0.57 vs. tertile high: HR=2.015 [1.169-3.471], *p*-FDR=0.39).
- 261

			Number	Number			FDR-
			of	of		p-	corrected
Subgroup	Cases	Controls	events	controls	HR (range)	value	<i>p-</i> value
	CRC						
Entire cohort	LS	CRC-free LS	701	727	1.016 (1.003-1.030)	0.019	0.056
MLH1	CRC LS	CRC-free LS	302	237	1.006 (0.986-1.026)	0.579	0.579
MSH2/EPCAM	CRC LS	CRC-free LS	275	239	1.016 (0.994-1.038)	0.154	0.305
MSH6	CRC LS	CRC-free LS	89	195	1.052 (1.012-1.092)	0.010	0.056
PMS2	CRC LS	CRC-free LS	35	56	1.037 (0.962-1.119)	0.339	0.407
Age <50y	CRC LS	CRC-free LS	501	727	1.019 (1.003-1.035)	0.019	0.019
Entire cohort	CRC LS	CRC-free population controls	701	5579	1.012 (0.999-1.024)	0.069	0.347
MLH1	CRC LS	CRC-free population controls	302	5579	1.007 (0.988-1.027)	0.470	0.564
MSH2/EPCAM	CRC LS	CRC-free population controls	275	5579	1.014 (0.994-1.034)	0.173	0.347
MSH6	CRC LS	CRC-free population controls	89	5579	1.015 (0.980-1.051)	0.400	0.564
PMS2	CRC LS	CRC-free population controls	35	5579	1.002 (0.928-1.081)	0.965	0.965
Age <50y	CRC LS	CRC-free population controls	501	5579	1.011 (0.996-1.025)	0.162	0.247
Entire cohort	CRC or AA LS	CRC-free and AA-free LS	733	695	1.019 (1.005-1.032)	0.005	0.033
MLH1	CRC or AA LS	CRC-free and AA-free LS	314	224	1.009 (0.992-1.025)	0.309	0.370
MSH2/EPCAM	CRC or AA LS	CRC-free and AA-free LS	292	222	1.016 (1.001-1.031)	0.037	0.056
MSH6	CRC or AA LS	CRC-free and AA-free LS	92	193	1.026 (1.004-1.049)	0.022	0.056
PMS2	CRC or AA LS	CRC-free and AA-free LS	35	56	1.010 (0.985-1.035)	0.447	0.447
Age <50y	CRC or AA LS	CRC-free and AA-free LS	524	695	1.022 (1.006-1.038)	0.007	0.006

TABLE 2. Meta-analysis results of the association between Polygenic risk score (rwPRS) and colorectal cancer (CRC) risk or CRC and advanced adenoma (AA) risk.

CRC LS: LS individuals previously diagnosed of CRC; *CRC-free* LS: LS individuals with no previous CRC diagnosis; CRC-free population control: individuals from the population without previous diagnosis of CRC; *CRC or AA* LS: LS individuals with a previous diagnosis of CRC or AA, whichever occurred first; *CRC-free and AA-free* LS: LS individuals not diagnosed with CRC or AA; *HR*:

Hazard ratio; *FDR* False discovery rate; *age <50y*: cases with CRC <50 years of age.

269 Subanalysis: multiple CRCs

270 Multiple CRCs as the study event

- 271 No statistically significant association of rwPRS with multiple CRC risk was observed
- 272 (irrespective of the gene involved) when comparing single-CRC LS cases, CRC-free LS
- individuals, or CRC-free population controls (*Table 3 and Tab. S6*). These analyses
- 274 could not be performed in *MSH6* or *PMS2* carriers due to the low sample sizes.
- 275 Multiple CRCs or AAs as study events
- A significant association of rwPRS with multiple CRC or AA risk was observed in LS
- individuals under 60 years when comparing with single-CRC or AA LS (HR=1.057
- 278 [1.010-1.100], *p*-FDR=0.04) and CRC-free and AA-free LS (HR=1.043 [1.008-1.079], *p*-
- 279 FDR=0.03). A tendency was observed for an association of rwPRS with multiple CRC or
- AA risk in the entire cohort and *MLH1* carriers (*Table 3 and Tab. S7*). These analyses
- could not be performed in *MSH6* and *PMS2* carriers due to the low sample size.

			Number	Number			FDR-
			of	of		p-	corrected
Subgroup	Cases	Controls	events	controls	OR (range)	value	<i>p</i> -value
Entire cohort	Multiple CRC LS	Single CRC LS	257	437	1.021 (0.992-1.051)	0.153	0.204
MLH1	Multiple CRC LS	Single CRC LS	112	185	1.044 (0.997-1.094)	0.067	0.204
MSH2/EPCAM	Multiple CRC LS	Single CRC LS	113	160	0.959 (0.907-1.014)	0.144	0.204
Age <60y	Multiple CRC LS	Single CRC LS	206	437	1.022 (0.992-1.053)	0.152	0.303
Entire cohort	Multiple CRC LS	CRC-free LS	257	727	1.025 (0.984-1.068)	0.227	0.454
MLH1	Multiple CRC LS	CRC-free LS	112	237	1.026 (0.970-1.084)	0.370	0.462
MSH2/EPCAM	Multiple CRC LS	CRC-free LS	113	239	1.023 (0.963-1.087)	0.462	0.462
Age <60y	Multiple CRC LS	CRC-free LS	206	727	1.032 (0.996-1.070)	0.084	0.167
Entire cohort	Multiple CRC LS	CRC-free population controls	257	5630	1.022 (0.991-1.055)	0.170	0.380
MLH1	Multiple CRC LS	CRC-free population controls	112	5630	1.027 (0.983-1.073)	0.228	0.380
MSH2/EPCAM	Multiple CRC LS	CRC-free population controls	113	5630	1.002 (0.958-1.047)	0.938	0.938
Age <60y	Multiple CRC LS	CRC-free population controls	206	5630	1.019 (0.987-1.052)	0.240	0.480
Entire cohort	Multiple CRC or AA LS	Single CRC or AA LS	272	454	1.030 (1.000-1.060)	0.035	0.104
MLH1	Multiple CRC or AA LS	Single CRC or AA LS	112	198	1.048 (1.000-1.100)	0.042	0.104
MSH2/EPCAM	Multiple CRC or AA LS	Single CRC or AA LS	123	167	0.992 (0.943-1.040)	0.740	0.740
Age <60y	Multiple CRC or AA LS	Single CRC or AA LS	219	454	1.034 (1.005-1.064)	0.023	0.046
Entire cohort	Multiple CRC or AA LS	CRC-free and AA-free LS	272	695	1.042 (1.010-1.080)	0.015	0.060
MLH1	Multiple CRC or AA LS	CRC-free and AA-free LS	112	224	1.030 (0.974-1.090)	0.303	0.303
MSH2/EPCAM	Multiple CRC or AA LS	CRC-free and AA-free LS	123	222	1.032 (0.975.1.090)	0.277	0.303
Age <60y	Multiple CRC or AA LS	CRC-free and AA-free LS	219	695	1.043 (1.008-1.079)	0.016	0.032

TABLE 3. Meta-analysis results of the association between polygenic risk score (rwPRS) and multiple colorectal cancer (CRC) risk or multiple CRC or advanced adenoma (AA) risk.

Multiple CRC LS: LS individuals previously diagnosed with more than one CRC; *Single CRC LS*: LS individuals previously diagnosed with one CRC; *CRC-free LS*: LS individuals without previous diagnosis of CRC; *CRC-free population*: individuals from the population without previous diagnosis of CRC; *Multiple CRC or AA LS*: LS individuals previously diagnosed of multiple CRCs, multiple AAs or at least one CRC and one AA; *Single CRC or AA LS*: LS individuals previously diagnosed of CRC or AA, whichever occurred first; *CRC-free and AA-free LS*: LS individuals without previous diagnosis of CRC or AA; *OR*: Odds ratio; *FDR*: False discovery rate; *Age <60y*: cases with CRC <60 years of age.

medRxiv preprint doi: https://doi.org/10.1101// (which was not certified by peer review) It is made

290 **DISCUSSION**

291 PRS is regarded as an important addition to the assessment of an individual's genetic 292 risk in patients with sporadic and hereditary cancers; it can be used to identify 293 individuals with a CRC risk several times lower or higher than that of the average 294 population. In this way, its implementation seems to be a promising approach for a more 295 individualised risk stratification. Several studies described the impact of PRS on modelling CRC risk in the general population^{10,12–16}. In line with this, the risk alleles of 296 297 those SNPs were found to accumulate in unexplained familial and early-onset CRC cases^{17,18}. However, the interplay between a PRS based on sporadic CRC-associated 298 299 SNPs and LS CRC risk remains controversial.

300 It is well known that among patients with hereditary CRC, in particular Lynch syndrome, 301 the age of onset and cumulative CRC incidence is very heterogeneous, even within the same family transmitting the same pathogenic germline variant⁶. The estimated gene-302 303 specific, individual lifetime CRC risks of LS patients with MLH1 or MSH2 variants can be 304 lower than 10% or as high as 90%-100% in a considerable fraction, highlighting relevant genetic and non-genetic modifiers of CRC risk^{7,8}. Initially, a small subset of common 305 CRC-associated SNPs was analysed in selected LS cohorts²⁹⁻³². More recently, some 306 307 studies used a more comprehensive set of around 100 CRC-associated SNPs in large population-based or familial CRC cohorts with conflicting results^{16,19,20}. 308

Herein, we used a large, combined cohort of 1,465 affected and unaffected LS patients with pathogenic MMR germline variants, recruited at two European centres based on the fulfilment of clinical criteria (revised Bethesda or Amsterdam criteria) or as a result of an EC or CRC-based LS screening programme, to evaluate to what extent the

313 polygenic background modulates CRC risk. When we compared LS carriers with CRC 314 against population-based CRC-free controls (mean age 71 years), we did not observe 315 any significant effect of PRS on CRC risk, neither in the entire cohort nor in subgroups 316 (gene-specific groups, early-onset group). Nevertheless, the PRS was associated with a 317 modestly increased risk of CRC or AA in the entire LS cohort. These results are in line 318 with the work by Jenkins et al., which is based on a similar study design, recruitment strategy, and a set of 107 SNPs used for PRS calculation²⁰. In that work, 826 European-319 320 descent LS carriers from the Colon Cancer Family Registry (CCFR) were included and 321 the authors found no statistical evidence of an association between PRS and CRC risk, 322 irrespective of sex or mutated gene.

323 Regarding the analysis between CRC and CRC-free LS probands, we did not find a 324 statistically significant association between CRC and PRS in the entire cohort or the 325 different subgroups except for early-onset LS CRC cases (<50 years) and LS with 326 multiple CRCs or AAs (< 60 years), where a slightly increased CRC risk was evidenced. 327 In contrast, two recent studies using UKBB data and the same 95 SNPs for PRS 328 calculation, demonstrated that the polygenic background substantially influences CRC 329 risk in LS with ORs ranging from 8 to 118 (estimated effect of PRS), or 4 to 16 330 (calculated effect of PRS) compared with the median tertile of the CRC-free population^{16,19}. According to these results, PRS would account for parts of the 331 332 interindividual variation in CRC risk among LS carriers and might contribute towards a 333 clinically relevant individualised risk stratification.

The most obvious explanation for the apparently discrepant results between familybased (Jenkins *et al.*,²⁰ and the present study) and population-based (Fahed *et al.*,¹⁶

and Hassanin *et al.*,¹⁹) studies is differences in study design and recruitment strategies. The LS probands from the two familial CRC registry studies were mainly recruited based on established clinical criteria, in particular early-onset and familial clustering of CRC and other LS-related tumours. Consistent with this ascertainment approach, the vast majority of participants carry pathogenic variants in the highly penetrant *MLH1* and *MSH2* genes (Table 4), which are likely to be less influenced by the genetic background.

In contrast, studies using individuals from a population-based repository (UKBB) show a different distribution of affected MMR genes, with the vast majority of LS individuals carrying pathogenic variants in the moderate and low penetrance genes *MSH6* or *PMS2* (**Table 4**). In a gene-specific analysis, Hassanin *et al.*, found that the modifying effect of the PRS is inversely related to the penetrance of the MMR gene, with the strongest effect in *MSH6* and *PMS2* carriers¹⁹, which are clearly underrepresented in the studies of Jenkins *et al.*,²⁰ and the present.

This is in line with hereditary breast cancer, where PRS has proven most relevant as a cancer risk modifier in carriers of pathogenic variants in moderate penetrance genes such as *CHEK2*, *ATM*, or *PALB2* compared with *BRCA1/2*^{33,34}. While it can be expected that PRS may have a major influence in less penetrant CRC risk genes, we have not been able to show a significant effect, likely due to the small numbers of *MSH6* and *PMS2* variant carriers present in our family-based cohorts due to the aforementioned selection bias.

Study	Inclusion	MLH1	MSH2 /	MSH6	PMS2	Cases	Controls	All
	criteria		EPCAM					

Fahed ¹⁶	Population-	19	6	43	8	11	65	76
	based	(25%)	(8%)	(57%)	(11%)	(14%)	(86%)	
Hassanin ¹⁹	Population-	11	13	135	229	27	361	388
	based	(3%)	(3%)	(35%)	(59%)	(7%)	(93%)	
Jenkins ²⁰	Family	293	336	126	71	504	322	826
	registry	(36%)	(41%)	(15%)	(9%)	(61%)	(39%)	
This study	Family	557	517	299	92	712	753	1465
	registry	(38%)	(35%)	(20%)	(6%)	(49%)	(51%)	

TABLE 4. Characteristics of inclusion criteria and distribution of affected MMR genes in the different studies analysing PRS in LS individuals.

360

361 Another plausible explanation for the differences observed may be the sample size. In this study, we included twice as many LS individuals as Jenkins et al.²⁰ and four and 20 362 times more than the UKBB analyses^{16,19}. Moreover, the distribution and composition of 363 364 cases and controls differ between family-registry and population-based studies (Table 4). In Jenkins et al., and our study, the percentages of affected (LS carriers with CRC) 365 366 and unaffected (CRC-free LS carriers) individuals are similar and some are members of 367 the same family. Hence, the CRC-free LS controls are relatives of the cases and, thus, 368 they likely share parts of the polygenic background and other risk factors with their 369 affected relatives (cases) to a certain extent, which may explain the observed missing 370 effect of PRS. In contrast, the UKBB studies include ten times more controls, 371 supposedly healthy LS carriers apparently unrelated to the CRC LS cases. In this regard, it was shown that both in sporadic CRC³⁵ and LS CRC¹⁹, family history and PRS 372 373 are largely independent and provide complementary information about CRC risk.

On the other hand, there are differences in the results obtained between Jenkins *et al.*,²⁰ and the present study. These differences can be explained by the sample size, as discussed above, and methodological differences. LS individuals in Jenkins *et al.*, were censored after a polypectomy, while we considered the first polypectomy as a time-

378 dependent variable of CRC risk, as per studies showing a reduction in CRC incidence in LS individuals undergoing regular colonoscopies^{36,37}. However, since alternative 379 380 pathways of colorectal carcinogenesis seem to exist in LS carriers, which originate 381 doubts regarding the risk-reducing impact of colonoscopies, especially in *MLH1* carriers, 382 future evidence will determine whether it is useful to apply this time-dependent variable correction in LS individuals^{38,39}. Taken together, this and previous PRS studies on LS 383 384 demonstrate that the study design and recruitment strategy strongly influence the 385 results and conclusions of the PRS.

Finally, when we analysed extreme phenotypes, such as early-onset CRC (<50y) and young (<60y) LS cases with multiple CRCs or AAs, a significant, albeit low, association between PRS and risk was observed, pointing to a possible contribution of PRS to these higher-risk situations.

Some authors questioned whether the same CRC-associated SNPs identified in the general population and their specific effect sizes can be applied to stratify CRC risk in LS individuals and whether both specific SNPs and their risk-modifying power may differ for each mutated gene^{8,20,29}. The potential identification of LS risk-modifier SNPs in large GWASs might contribute to the description of more specific risk-modulating factors in the future.

396 PRS studies in much larger, international, multicentric, LS cohorts are needed to more 397 precisely estimate the PRS effect size in LS individuals, especially in those with extreme 398 phenotypes, to evaluate the relevance of the polygenic background and interplay with 399 other genetic and non-genetic risk factors. This will enable its eventual application in 400 routine clinical practice.

- 401 In summary, this work shows, for the first time in a family-registry LS cohort, that the
- 402 PRS can influence the CRC risk in specific subgroups of LS individuals, albeit with very
- 403 weak effect sizes, which contrasts with the clearer modulating effect of the PRS in LS
- 404 carriers identified in population-based cohorts.

405 **ACKNOWLEDGEMENTS:** We thank the participating patients and families and all members of 406 the Units of Genetic Counseling and Genetic Diagnostic of the Hereditary Cancer Program of 407 the Catalan Institute of Oncology (ICO-IDIBELL) and the Institute of Human Genetics of the 408 University Hospital Bonn as well as the BufaLynch association for their support and funding of 409 ICO's Lynch Syndrome Database. We thank Gemma Aiza for technical support. The authors 410 would also like to acknowledge the Department of Medicine at the Universitat Autònoma de 411 Barcelona and the CERCA Program/Generalitat de Catalunya for institutional support.

412 **COMPETING INTERESTS**: The authors declare no conflicts of interest.

413 FUNDING: This research has been funded by the Instituto de Salud Carlos III and co-funded by 414 the European Social Fund—ESF investing in your future (grant CM19/00099), the Catalan-415 Balearic Society of Oncology (2018 grant of the Catalan-Balearic Society of Oncology), the 416 European Union's Horizon 2020 research and innovation program under the EJP RD COFUND-417 EJP nº 825575, the Spanish Ministry of Economy and Competitiveness and the Spanish 418 Ministry of Science and Innovation, co-funded by FEDER funds -a way to build Europe-419 (grants SAF2015-68016-R and PID2019-111254RB-I00), CIBERONC (CB16/12/00234) and the 420 Government of Catalonia (SGR_01112). ADV and VM are part of group 55 of CIBERESP. The 421 GSA genotyping was performed at the Spanish National Cancer Research Centre, in the 422 Human Genotyping lab, a member of CeGen, PRB3, and is supported by grant PT17/0019, of 423 the PE I+D+i 2013-2016, funded by ISCIII and ERDF. ADV was supported by PERIS contract 424 SLT017/20/000042. This research was partially funded by public grants from the Spanish 425 Association Against Cancer (AECC) Scientific Foundation—grant GCTRA18022MORE—and 426 Spanish Ministry for Economy and Competitivity, Instituto de Salud Carlos III, co-funded by 427 FEDER funds –a way to build Europe (FIS PI14-00613).

428 **AUTHOR CONTRIBUTIONS**:

429 <u>Núria Dueñas</u> – Study concept and design, Analysis and interpretation of data, Drafting of the

430 manuscript, Critical revision of the manuscript for important intellectual content

- 431 Hannah Klinkhammer, Nuria Bonifaci, Anna Diez-Villanueva Study concept and design,
- 432 Statistical analysis, Analysis and interpretation of data, Drafting of the manuscript, Critical
- 433 revision of the manuscript for important intellectual content
- 434 Andreas Mayr, Emadeldin Hassanin, Carlo Maj Study concept and design, Statistical analysis,
- 435 Analysis and interpretation of data, Critical revision of the manuscript for important intellectual
- 436 content
- 437 <u>Anna Díez-Villanueva, Victor Moreno</u> Study concept and design, Critical revision of the
- 438 manuscript for important intellectual content
- 439 Isabel Spier, Marta Pineda, Gabriel Capellá, Stefan Aretz, Joan Brunet Study concept and
- 440 design, Analysis and interpretation of data, Critical revision of the manuscript for important
- 441 intellectual content, Study supervision
- 442
- 443
- 444
- 445

446 **REFERENCES**

- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN
 Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
 CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
- 450 2. Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of
 451 cancer among 9.6 million individuals in the Swedish Family-Cancer Database. Int
 452 J cancer. 2002;99(2):260-266. doi:10.1002/ijc.10332
- 453
 453
 454
 454
 454
 455
 455
 455
 455
 456
 457
 457
 458
 459
 459
 459
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
- 456
 457
 458
 458
 458
 457
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
 458
- 459 5. Hampel H, de la Chapelle A. How do we approach the goal of identifying
 460 everybody with Lynch syndrome? *Fam Cancer*. 2013;12(2):313-317.
 461 doi:10.1007/s10689-013-9611-5
- 462
 6. Dominguez-Valentin M, Sampson JR, Seppälä TT, et al. Cancer risks by gene,
 463 age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings
 464 from the Prospective Lynch Syndrome Database. *Genet Med.* 2020;22(1):15-25.
 465 doi:10.1038/s41436-019-0596-9
- 466
 467
 468
 468
 468
 468
 469
 469
 469
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
- 4698.Scott RJ. Modifier genes and Lynch syndrome: some considerations. Hered470Cancer Clin Pract. 2022;20(1):35. doi:10.1186/s13053-022-00240-2
- 471 9. Law PJ, Timofeeva M, Fernandez-Rozadilla C, et al. Association analyses identify
 472 31 new risk loci for colorectal cancer susceptibility. *Nat Commun.*473 2019;10(1):2154. doi:10.1038/s41467-019-09775-w
- Huyghe JR, Bien SA, Harrison TA, et al. Discovery of common and rare genetic
 risk variants for colorectal cancer. *Nat Genet.* 2019;51(1):76-87.
 doi:10.1038/s41588-018-0286-6
- 477 11. Fernandez-Rozadilla C, Timofeeva M, Chen Z, et al. Deciphering colorectal 478 cancer genetics through multi-omic analysis of 100,204 cases and 154,587 479 controls of European and east Asian ancestries. *Nat Genet*. Published online 480 December 20, 2022. doi:10.1038/s41588-022-01222-9
- Hsu L, Jeon J, Brenner H, et al. A model to determine colorectal cancer risk using
 common genetic susceptibility loci. *Gastroenterology*. 2015;148(7):13301339.e14. doi:10.1053/j.gastro.2015.02.010
- 484
 485
 486
 486
 486
 487
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
- 487 14. Frampton MJE, Law P, Litchfield K, et al. Implications of polygenic risk for
- 488 personalised colorectal cancer screening. *Ann Oncol.* 2016;27(3):429-434.
 489 doi:10.1093/annonc/mdv540
- 490 15. Thomas M, Sakoda LC, Hoffmeister M, et al. Genome-wide Modeling of Polygenic


491		Risk Score in Colorectal Cancer Risk. Am J Hum Genet. 2020;107(3):432-444.
492		doi:10.1016/j.ajhg.2020.07.006
493	16.	Fahed AC, Wang M, Homburger JR, et al. Polygenic background modifies
494		penetrance of monogenic variants for tier 1 genomic conditions. Nat Commun.
495		2020;11(1). doi:10.1038/s41467-020-17374-3
496	17.	Archambault AN, Su Y-R, Jeon J, et al. Cumulative Burden of Colorectal Cancer-
497		Associated Genetic Variants Is More Strongly Associated With Early-Onset vs
498		Late-Onset Cancer. Gastroenterology. 2020;158(5):1274-1286.e12.
499		doi:10.1053/j.gastro.2019.12.012
500	18.	Mur P, Bonifaci N, Díez-Villanueva A, et al. Non-lynch familial and early-onset
501		colorectal cancer explained by accumulation of low-risk genetic variants. Cancers
502		(Basel). 2021;13(15). doi:10.3390/cancers13153857
503	19.	Hassanin E, Spier I, Bobbili DR, et al. Clinically relevant combined effect of
504		polygenic background, rare pathogenic germline variants, and family history on
505		colorectal cancer incidence. <i>BMC Med Genomics</i> . 2023;16(1):42.
506		doi:10.1186/s12920-023-01469-z
507	20.	Jenkins MA, Buchanan DD, Lai J, et al. Assessment of a Polygenic Risk Score for
508		Colorectal Cancer to Predict Risk of Lynch Syndrome Colorectal Cancer. JNCI
509		cancer Spectr. 2021;5(2):pkab022. doi:10.1093/jncics/pkab022
510	21.	Dueñas N, Navarro M, Sanjuán X, et al. Lessons learnt from the implementation
511		of a colorectal cancer screening programme for lynch syndrome in a tertiary
512		public hospital. <i>Cancer Epidemiol.</i> 2023;82. doi:10.1016/j.canep.2022.102291
513	22.	Obón-Santacana M, Díez-Villanueva A, Alonso MH, et al. Polygenic risk score
514		across distinct colorectal cancer screening outcomes: from premalignant polyps to
515		colorectal cancer. <i>BMC Med</i> . 2021;19(1). doi:10.1186/s12916-021-02134-x
516	23.	Schmermund A, Möhlenkamp S, Stang A, et al. Assessment of clinically silent
517		atherosclerotic disease and established and novel risk factors for predicting
518		myocardial infarction and cardiac death in healthy middle-aged subjects:
519		Rationale and design of the Heinz Nixdorf RECALL study. Am Heart J.
520		2002;144(2):212-218. doi:10.1067/mhj.2002.123579
521	24.	Das S, Forer L, Schönherr S, et al. Next-generation genotype imputation service
522		and methods. <i>Nat Genet</i> . 2016;48(10):1284-1287. doi:10.1038/ng.3656
523	25.	Auton A, Abecasis GR, Altshuler DM, et al. A global reference for human genetic
524		variation. <i>Nature</i> . 2015;526(7571):68-74. doi:10.1038/nature15393
525	26.	Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome
526		association and population-based linkage analyses. Am J Hum Genet.
520 527		2007;81(3):559-575. doi:10.1086/519795
528	27.	Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: A
529		practical tutorial. <i>Evid Based Ment Health</i> . 2019;22(4):153-160.
530		doi:10.1136/ebmental-2019-300117
531	28.	Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and
532		Powerful Approach to Multiple Testing. J R Stat Soc Ser B. 1995;57(1):289-300.
533		doi:https://doi.org/10.1111/j.2517-6161.1995.tb02031.x
534	29.	Win AK, Hopper JL, Buchanan DD, et al. Are the common genetic variants
535		associated with colorectal cancer risk for DNA mismatch repair gene mutation
536		carriers? <i>Eur J Cancer</i> . 2013;49(7):1578-1587. doi:10.1016/j.ejca.2013.01.029

- ten Broeke SW, Elsayed FA, Pagan L, et al. SNP association study in PMS2associated Lynch syndrome. *Fam Cancer*. 2018;17(4):507-515.
 doi:10.1007/s10689-017-0061-3
- 54031.Talseth-Palmer BA, Wijnen JT, Brenne IS, et al. Combined analysis of three lynch541syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1542mutation carriers. Int J Cancer. 2013;132(7):1556-1564. doi:10.1002/ijc.27843
- 543 32. Houlle S, Charbonnier F, Houivet E, et al. Evaluation of Lynch syndrome modifier
 544 genes in 748 MMR mutation carriers. *Eur J Hum Genet*. 2011;19(8):887-892.
 545 doi:10.1038/eihg.2011.44
- 546 33. Gallagher S, Hughes E, Wagner S, et al. Association of a Polygenic Risk Score
 547 with Breast Cancer among Women Carriers of High- And Moderate-Risk Breast
 548 Cancer Genes. JAMA Netw Open. 2020;3(7).
- 549 doi:10.1001/jamanetworkopen.2020.8501
- 55034.Hassanin E, May P, Aldisi R, et al. Breast and prostate cancer risk: The interplay551of polygenic risk, rare pathogenic germline variants, and family history. Genet552Med. 2022;24(3):576-585. doi:10.1016/j.gim.2021.11.009
- Mars N, Lindbohm J V., della Briotta Parolo P, et al. Systematic comparison of
 family history and polygenic risk across 24 common diseases. *Am J Hum Genet*.
 Published online December 2022. doi:10.1016/j.ajhg.2022.10.009
- 556 36. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening 557 for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. 558 *Gastroenterology*. 2000;118(5):829-834. doi:10.1016/S0016-5085(00)70168-5
- Kalady MF, Lipman J, McGannon E, Church JM. Risk of colonic Neoplasia after
 proctectomy for rectal cancer in hereditary Nonpolyposis Colorectal cancer. *Ann Surg.* 2012;255(6):1121-1125. doi:10.1097/SLA.0b013e3182565c0b
- 38. Ahadova A, Gallon R, Gebert J, et al. Three molecular pathways model colorectal
 carcinogenesis in Lynch syndrome. *Int J Cancer*. 2018;143(1):139-150.
 doi:10.1002/ijc.31300
- 565 39. Seppälä T, Pylvänäinen K, Evans DG, et al. Colorectal cancer incidence in
 566 path_MLH1 carriers subjected to different follow-up protocols: a Prospective
 567 Lynch Syndrome Database report. *Hered Cancer Clin Pract.* 2017;15:18.
- 568 doi:10.1186/s13053-017-0078-5

570 FIGURE LEGENDS


571 FIGURE 1. Interplay of each mutated germline gene and polygenic risk score (rwPRS) for colorectal cancer (CRC) risk. CRC risk for each mutated gene, stratified 572 573 according to rwPRS tertiles using the intermediate rwPRS tertile as the reference group. 574 95% confidence intervals are indicated by vertical lines. PMS2 carriers are not included 575 due to the low sample size. 576 577 FIGURE 2. Interplay of each mutated germline gene and polygenic risk score (rwPRS) for colorectal cancer (CRC) or advanced adenoma (AA) risk. Risk of CRC 578 579 or AA for each mutated gene, stratified according to rwPRS tertiles using the

580 intermediate rwPRS tertile as the reference group. 95% confidence intervals are 581 indicated by vertical lines. PMS2 carriers are not included due to the low sample size.



PRS





PRS

